Case Reports
doi: 10.1378/chest.99.4.1025.
Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis
Affiliations
- PMID: 1901260
- DOI: 10.1378/chest.99.4.1025
Item in Clipboard
Case Reports
Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis
Chest.
1991 Apr.
Abstract
This report describes two patients with multidrug resistant tuberculosis who were successfully treated with the addition of amoxicillin-clavulanic acid to second-line drugs. Mycobacterium tuberculosis possesses a beta-lactamase contributing to its resistance to beta-lactam antibiotics. The combination of clavulanic acid, a beta-lactamase inhibitor, and amoxicillin has been shown bactericidal for M tuberculosis in vitro. These data suggest that resistant tuberculosis may warrant a trial of treatment including amoxicillin-clavulanic acid.
Similar articles
-
Use of amikacin and amoxicillin-clavulanic acid against Mycobacterium tuberculosis.Chest. 1993 Jul;104(1):328. doi: 10.1378/chest.104.1.328b. Chest. 1993. PMID: 8325113 No abstract available.
-
Activity of amoxicillin/clavulanate in patients with tuberculosis.Clin Infect Dis. 1998 Apr;26(4):874-7. doi: 10.1086/513945. Clin Infect Dis. 1998. PMID: 9564467 Clinical Trial.
-
Acquired resistance of Nocardia brasiliensis to clavulanic acid related to a change in beta-lactamase following therapy with amoxicillin-clavulanic acid.Antimicrob Agents Chemother. 1991 Mar;35(3):524-8. doi: 10.1128/AAC.35.3.524. Antimicrob Agents Chemother. 1991. PMID: 2039203 Free PMC article.
-
[Usefulness of an amoxicillin/clavulanic-acid combination in respiratory tract infection: bacterial resistance and antibiotic therapy].Minerva Pediatr. 1990 Jan-Feb;42(1-2):29-34. Minerva Pediatr. 1990. PMID: 2186263 Review. Italian.
-
Beta-lactamase inhibitors: another approach to overcoming antimicrobial resistance.Infect Control. 1987 Jan;8(1):36-40. doi: 10.1017/s0195941700066972. Infect Control. 1987. PMID: 3028975 Review.
Cited by
-
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening.PLoS Negl Trop Dis. 2019 Jan 28;13(1):e0007126. doi: 10.1371/journal.pntd.0007126. eCollection 2019 Jan. PLoS Negl Trop Dis. 2019. PMID: 30689630 Free PMC article.
-
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142. doi: 10.1164/rccm.201909-1874ST. Am J Respir Crit Care Med. 2019. PMID: 31729908 Free PMC article.
-
Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.PLoS One. 2019 May 10;14(5):e0215607. doi: 10.1371/journal.pone.0215607. eCollection 2019. PLoS One. 2019. PMID: 31075149 Free PMC article.
-
Drug-Resistant Tuberculosis: Challenges and Progress.Infect Dis Clin North Am. 2016 Jun;30(2):509-522. doi: 10.1016/j.idc.2016.02.010. Infect Dis Clin North Am. 2016. PMID: 27208770 Free PMC article. Review.
-
Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions.ACS Infect Dis. 2022 Mar 11;8(3):557-573. doi: 10.1021/acsinfecdis.1c00570. Epub 2022 Feb 22. ACS Infect Dis. 2022. PMID: 35192346 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
